Francois Cedric's Form 4 filing
Apellis Pharmaceuticals, Inc. (APLS) · filed Jan 17, 2024
- Accession no.
- 0001127602-24-001431
- Filed
- Jan 17, 2024
- Trade date
- Jan 16, 2024
- Filing delay
- 1 day
- Rule 10b5-1 plan
- Not checked
This filing lists 2 non-derivative transactions and 1 derivative transaction. Open-market sales total $524.5K. It was filed 1 day after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Francois CedricCIK 0001658080 | Director, Officer (Chief Executive Officer) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Jan 16, 2024 | Common Stock | AGrant or awardAcquired | +72,094 | $0.00 | $0 | 341,749 | Direct | |
| Jan 16, 2024 | Common Stock | SSaleDisposed | −7,851 | $66.81 | −$524,525.31 | 333,898 | Direct |
Derivative securities (Table II)
Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.
| Trade date | Security | Transaction | Underlying shares | Unit price | Value | Held after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Jan 16, 2024 | Common Stock | AGrant or awardAcquired | +104,834 | $66.30 | +$6,950,494.2 | 104,834 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
No transaction price on this filing refers to a footnote.